Skip to main content

Fresenius Kabi introduces pediatric cancer generic

5/16/2017

LAKE ZURICH, Ill. — Fresenius Kabi announced on Tuesday the immediate availability in the United States of its first-to-market generic of Genzyme’s Clolar (clofarabine injection). Fresenius Kabi’s clofarabine injection is available as a single dose vial containing 20 mg per 20 mL clofarabine.


 “Fresenius Kabi is pleased to introduce a generic version of this important pediatric cancer medicine,” said John Ducker, president and CEO of Fresenius Kabi USA. “Continuing to develop critical and accessible medicines for all patients is fundamental to the Fresenius Kabi mission of ‘caring for life.’”


Clofarabine injection is a purine nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. This indication is based upon response rate.


Lake Zurich-based Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients.


X
This ad will auto-close in 10 seconds